← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $166B	2,377	-14	-0.6%	$176B
2	2 Amgen AMGN $230B	1,865	-22	-1%	$86B
3	3 Eli Lilly LLY $1.08T	1,516	-89	-6%	$83.5B
4	4 Becton Dickinson BDX $51.5B	1,374	-8	-0.6%	$58.1B
5	5 McKesson MCK $114B	841	-15	-2%	$21.8B
6	6 Conagra Brands CAG $6.61B	662	-40	-6%	$11.3B
7	7 Regeneron Pharmaceuticals REGN $80.1B	658	-61	-8%	$23.1B
8	8 Lamb Weston LW $7.31B	599	-46	-7%	$8.25B
9	9 Novo Nordisk NVO $168B	559	-21	-4%	$8.91B
10	10 AstraZeneca AZN $251B	547	-15	-3%	$19B
11	11 ResMed RMD $33.1B	485	+7	+1%	$11.8B
12	12 Teva Pharmaceutical Industries Limited TEVA $47.5B	452	-70	-13%	$5.92B
13	13 DaVita DVA $11.5B	400	-40	-9%	$8.54B
14	14 West Pharmaceutical WST $26.4B	374	-5	-1%	$8.59B
15	15 DELISTED CATALENT, INC. CTLT	288	+5	+2%	$8.33B
16	16 Medifast MED $132M	251	+5	+2%	$1.53B
17	17 Herbalife HLF $1.49B	217	-52	-19%	$6.06B
18	ARNA 18 DELISTED Arena Pharmaceuticals Inc ARNA	215	+31	+17%	$2.47B
19	19 DELISTED WW International WW	212	+3	+1%	$1.11B
20	20 Opko Health OPK $1.02B	200	-1	-0.5%	$377M
21	21 Tootsie Roll Industries TR $2.87B	187	-1	-0.5%	$595M
22	22 Fresenius Medical Care FMS $11.5B	175	-7	-4%	$352M
23	23 Accendra Health ACH $24.1M	173	-14	-7%	$173M
24	TWNK 24 DELISTED Hostess Brands, Inc. Class A Common Stock TWNK	167	+12	+8%	$1.79B
25	25 Viking Therapeutics VKTX $3.24B	156	-9	-5%	$374M